Company intelligence / Profile preview
Kolon TissueGene, Inc.
Rockville, Maryland, United Statestissuegene.com ↗
- Ownership
- Public · 950160
- Employees
- ~57
- Development stage
- Other
01
Overview
Kolon TissueGene’s lead product TG-C/Invossa has demonstrated efficacy in reducing pain and improving function for osteoarthritis of the knee. The company has completed Phase II clinical trials in the US and plans to initiate Phase III studies. Invossa has been commercialized outside the US but faced regulatory challenges previously; current focus remains on advancing through late-stage clinical development for broader approval.
- Therapeutic areas
- OtherImmunologyNeurologyRheumatology
- Modalities
- Cell therapy (allogeneic cell therapy)Gene therapyRegenerative medicine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Financials
- Market cap
- $820.7M
- Total revenue
- $3.8M
- Enterprise value
- $796.5M
Beyond the preview
Go deeper on Kolon TissueGene, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kolon TissueGene, Inc..